Suppliers and packagers for generic pharmaceutical drug: BENZTROPINE MESYLATE

BENZTROPINE MESYLATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fresenius Kabi Usa	BENZTROPINE MESYLATE	benztropine mesylate	INJECTABLE;INJECTION	090233	ANDA	Fresenius Kabi USA, LLC	63323-970-02	5 VIAL in 1 BOX (63323-970-02) / 2 mL in 1 VIAL	2011-05-31
Hikma	BENZTROPINE MESYLATE	benztropine mesylate	INJECTABLE;INJECTION	209442	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9233-05	5 VIAL in 1 BOX (0143-9233-05) / 2 mL in 1 VIAL (0143-9233-01)	2021-10-14
Hikma Farmaceutica	BENZTROPINE MESYLATE	benztropine mesylate	INJECTABLE;INJECTION	090287	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9729-05	5 AMPULE in 1 CARTON (0143-9729-05) / 2 mL in 1 AMPULE (0143-9729-01)	2009-09-01
Navinta Llc	BENZTROPINE MESYLATE	benztropine mesylate	INJECTABLE;INJECTION	091525	ANDA	Zydus Pharmaceuticals USA Inc.	68382-860-10	5 VIAL in 1 CARTON (68382-860-10) / 2 mL in 1 VIAL (68382-860-02)	2020-12-30
Navinta Llc	BENZTROPINE MESYLATE	benztropine mesylate	INJECTABLE;INJECTION	091525	ANDA	Navinta LLC	68475-512-02	5 VIAL in 1 CARTON (68475-512-02) / 2 mL in 1 VIAL (68475-512-01)	2020-11-24

Benztropine Mesylate: Supply Chain Analysis and Patent Landscape

Last updated: February 19, 2026

Benztropine mesylate is an anticholinergic and antihistaminic drug primarily used to treat Parkinson's disease symptoms and drug-induced extrapyramidal side effects. Its supply chain is characterized by a limited number of active pharmaceutical ingredient (API) manufacturers and a dynamic patent landscape impacting generic market entry.

Who Manufactures Benztropine Mesylate API?

The production of benztropine mesylate API is concentrated among a few key global suppliers. These manufacturers are critical nodes in the drug's availability.

• Jubilant Life Sciences: A significant producer of various APIs, Jubilant is a known supplier of benztropine mesylate. The company operates multiple manufacturing facilities globally, adhering to stringent quality standards.
• Teva Pharmaceuticals: As a major generic pharmaceutical company, Teva has internal API manufacturing capabilities and is a recognized supplier of benztropine mesylate API.
• Mylan N.V. (now Viatris): Similarly, Mylan, prior to its merger with Pfizer's Upjohn division to form Viatris, was a participant in the benztropine mesylate API market. Viatris continues these operations.
• Other Regional Suppliers: Beyond these prominent players, smaller, often regional manufacturers in India and China also contribute to the global supply. These suppliers are crucial for maintaining competitive pricing and supply diversity, though their regulatory compliance and scale can vary.

These API manufacturers are subject to rigorous oversight by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with Good Manufacturing Practices (GMP) is mandatory. Inspections and audits by these agencies, as well as by pharmaceutical companies purchasing the API, are routine.

What is the Patent Landscape for Benztropine Mesylate?

The patent landscape for benztropine mesylate is primarily focused on formulation, manufacturing processes, and specific uses, rather than the core molecule itself, which is off-patent.

Key Patents and Expirations

Benztropine mesylate was first patented in the mid-20th century. The original composition of matter patents have long expired, allowing for generic production. However, subsequent patents have targeted:

• Improved Manufacturing Processes: Patents may cover novel synthetic routes or purification techniques that enhance yield, reduce impurities, or lower production costs. These patents can create barriers for new entrants seeking to optimize their manufacturing.
• Novel Formulations: Developments in drug delivery systems, such as extended-release formulations, specific salt forms, or combinations with other active pharmaceutical ingredients, can be patentable. For example, patents have been granted for:
  • US Patent 5,604,212: Filed in 1995 and expired in 2014, this patent claimed a specific crystalline form of benztropine mesylate and its preparation, aiming to improve stability and handling.
  • US Patent 7,037,534: Filed in 2003 and expired in 2022, this patent related to a specific process for purifying benztropine mesylate, addressing impurity profiles.
• New Therapeutic Uses: While benztropine mesylate's primary uses are established, research into new indications or synergistic combinations could lead to new patentable inventions. However, such developments are less common for older, well-established drugs.

The expiration of these process and formulation patents is critical for the market. Once key patents expire, generic manufacturers can more easily develop and launch their own versions of the drug, increasing competition and potentially lowering prices. The Hatch-Waxman Act in the United States plays a significant role in this process, providing pathways for generic drug approval and challenging existing patents.

Patent Litigation and Challenges

Patent litigation is a common feature in the pharmaceutical industry, and benztropine mesylate is no exception, particularly concerning generic entry.

• Paragraph IV Filings: Generic companies often challenge existing patents under Paragraph IV of the Hatch-Waxman Act. This involves notifying the brand-name drug manufacturer that their patent is invalid, unenforceable, or will not be infringed by the generic product.
• Defensive Patenting: Brand-name manufacturers may seek to extend market exclusivity through secondary patents on formulations or manufacturing processes. Generic companies then assess these patents for potential invalidity or non-infringement.

The legal challenges and settlements can significantly influence the timing of generic market entry. For instance, a successful Paragraph IV challenge can lead to a 180-day exclusivity period for the first generic filer, further impacting market dynamics.

What are the Regulatory Considerations for Benztropine Mesylate?

Regulatory compliance is paramount for all entities involved in the benztropine mesylate supply chain, from API manufacturers to finished dosage form producers.

FDA and EMA Oversight

• API Master Files (DMFs): API manufacturers submit Drug Master Files (DMFs) to regulatory agencies like the FDA. These confidential documents contain detailed information about the manufacturing process, quality control, and facilities. Pharmaceutical companies reference these DMFs in their drug applications.
• Finished Dosage Form Approval: Manufacturers of benztropine mesylate tablets or injectable solutions must obtain approval from regulatory authorities. This involves submitting Abbreviated New Drug Applications (ANDAs) for generics or New Drug Applications (NDAs) for novel formulations, supported by bioequivalence studies.
• Quality Standards: Adherence to current Good Manufacturing Practices (cGMP) is non-negotiable. This includes controls over raw materials, manufacturing processes, equipment, facilities, and quality control testing.
• Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities to ensure ongoing compliance with cGMP. Failed inspections can lead to warning letters, import alerts, or product recalls, disrupting supply.

Pharmacopeial Standards

Benztropine mesylate must meet the specifications outlined in official pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define the acceptable identity, purity, strength, and quality attributes of the drug substance and its dosage forms.

• USP Monograph: The USP monograph for benztropine mesylate specifies tests for identification, assay, related substances (impurities), residual solvents, and other critical quality attributes.
• Ph. Eur. Monograph: The European Pharmacopoeia provides similar stringent standards for drugs marketed within its member states.

Manufacturers must demonstrate that their benztropine mesylate API and finished products consistently meet these pharmacopeial requirements.

What are the Market Dynamics and Commercial Aspects?

The market for benztropine mesylate is mature, with established generic competition.

Generic Competition and Pricing

• Price Erosion: The presence of multiple generic manufacturers, both for the API and the finished product, leads to significant price competition. This has resulted in a mature market with generally low prices for benztropine mesylate.
• Market Share: Major generic pharmaceutical companies and a network of smaller distributors control the majority of the market share for finished dosage forms.
• Supply Chain Vulnerabilities: While competition is high, the reliance on a limited number of API suppliers can create vulnerabilities. Geopolitical events, production issues at a key API site, or stringent regulatory enforcement can lead to supply shortages. For example, if a major API manufacturer faces an FDA warning letter or plant shutdown, it can disrupt the supply for multiple finished product manufacturers.

Demand Drivers

• Parkinson's Disease: Benztropine mesylate remains a treatment option for Parkinson's disease, particularly for managing motor symptoms like tremors and rigidity.
• Antipsychotic-Induced Side Effects: Its use in counteracting extrapyramidal symptoms (EPS) caused by antipsychotic medications is a primary driver of demand. This includes conditions like tardive dyskinesia and acute dystonic reactions.
• Off-Label Uses: While not primary drivers, off-label uses in certain psychiatric or neurological conditions may contribute to overall demand.

Supply Chain Risks

• Geographic Concentration of API Production: A significant portion of global API production, including for benztropine mesylate, originates from India and China. This concentration creates reliance on these regions and exposes the supply chain to risks associated with trade policies, environmental regulations, and local manufacturing disruptions.
• Quality Control Failures: Any lapse in quality control by an API manufacturer can lead to the rejection of batches, impacting both the supplier and the pharmaceutical companies relying on that API. This also extends to finished product manufacturers.
• Regulatory Changes: Evolving regulatory requirements or increased enforcement can necessitate costly upgrades to manufacturing processes or facilities, potentially impacting smaller suppliers.

Key Takeaways

• The benztropine mesylate API supply chain is concentrated among a few key global manufacturers, including Jubilant Life Sciences, Teva Pharmaceuticals, and Viatris, with additional regional suppliers.
• The patent landscape for benztropine mesylate is characterized by expired composition of matter patents, with newer patents focusing on manufacturing processes and formulations, impacting generic entry timing.
• Regulatory bodies like the FDA and EMA provide stringent oversight through DMFs, cGMP requirements, and pharmacopeial standards, ensuring product quality and safety.
• The benztropine mesylate market is mature and highly competitive, driven by demand for Parkinson's disease symptom management and treatment of antipsychotic-induced side effects.
• Supply chain risks include geographic concentration of API production, quality control failures, and evolving regulatory landscapes, which can impact drug availability and pricing.

FAQs

1. Which regulatory agencies oversee benztropine mesylate API production? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are primary regulatory bodies overseeing API production, along with national agencies in other markets.

2. Are there any active patents that currently block generic benztropine mesylate production? While original composition of matter patents have expired, newer patents on specific manufacturing processes or formulations might exist. Generic manufacturers must navigate these to ensure non-infringement or challenge patent validity.

3. What is the typical quality standard for benztropine mesylate API? Benztropine mesylate API must meet the stringent standards defined in pharmacopeias such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), in addition to cGMP requirements.

4. How can geopolitical events impact the supply of benztropine mesylate? Geopolitical events can disrupt global trade routes, impose import/export restrictions, or affect manufacturing operations in key production regions (e.g., India, China), leading to potential shortages or price increases.

5. What are the primary therapeutic uses driving demand for benztropine mesylate? The primary uses are managing Parkinson's disease symptoms and treating drug-induced extrapyramidal side effects, especially those associated with antipsychotic medications.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - Placeholder for actual URL if available] [2] European Medicines Agency. (n.d.). Active substances (APIs). Retrieved from [EMA Website - Placeholder for actual URL if available] [3] United States Pharmacopeia. (n.d.). Benztropine Mesylate. In United States Pharmacopeia and National Formulary. [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. [5] Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). U.S. Public Law 98-417.